Isoniazid Therapeutic Drug Monitoring in Tunisian Patients With Tuberculosis.
Acetylation
Adolescent
Adult
Age Factors
Antitubercular Agents
/ pharmacokinetics
Body Weight
Child
Child, Preschool
Dose-Response Relationship, Drug
Drug Monitoring
Female
Humans
Infant
Isoniazid
/ pharmacokinetics
Male
Middle Aged
Retrospective Studies
Sex Factors
Tuberculosis
/ drug therapy
Tunisia
acetylation index
isoniazid
pediatric
pharmacokinetics
therapeutic drug monitoring
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
24
10
2020
accepted:
04
01
2021
pubmed:
6
1
2021
medline:
21
12
2021
entrez:
5
1
2021
Statut:
ppublish
Résumé
A regular therapeutic drug monitoring (TDM) of isoniazid could be useful to predict the acetylation profile and to prescribe doses associated with optimal efficacy and safety. We aimed to assess the usefulness of isoniazid TDM in the Tunisian population, to describe the acetylation profile distribution in this population, and to investigate the influence of certain parameters on acetylation phenotype. We performed a retrospective study including Tunisian patients with tuberculosis underwent an isoniazid TDM. Isoniazid concentrations were measured 3 hours after drug intake (C
Substances chimiques
Antitubercular Agents
0
Isoniazid
V83O1VOZ8L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
972-978Informations de copyright
© 2021, The American College of Clinical Pharmacology.
Références
Mostowy S, Behr MA. The origin and evolution of Mycobacterium tuberculosis. Clin Chest Med. 2005;26(2):207-216, v-vi.
World Health Organization. Global tuberculosis report 2018. http://www.who.int/tb/publications/global_report/en/. Accessed September 28, 2019.
DSSB: Le guide national de prise en charge de la tuberculose édition 2018 - Ministère de la santé publique. http://www.santetunisie.rns.tn/fr/toutes-les-actualites/807-dssb-le-guide-national-de-prise-en-charge-de-la-tuberculose-%C3%A9dition-2018. Accessed March 15, 2020.
Ben Fredj N, Gam R, Kerkni E, et al. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients. Pharmacogenomics J. 2017;17(4):372-377.
Butcher NJ, Boukouvala S, Sim E, Minchin RF. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J. 2002;2(1):30-42.
Wilkins JJ, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson USH. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol. 2011;72(1):51-62.
Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62(15):2169-2183.
Vivien J, Thibier R. La pharmacocinétique de l'isoniazide dans la race blanche. Rev Fr Mal Respir. 1973;1:753-772.
Toure A, Cabral M, Niang A, et al. Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients. Toxicol Rep. 2016;3:826-831.
Alshaikheid M, Ben Fredj N, Chaabane A, et al. Development and validation of a chromatographic method for the quantification of Isoniazid in human plasma. J Pharm Drug Deliv Res. 2018;07(01):1-5.
Heysell SK, Moore JL, Staley D, Dodge D, Houpt ER. Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USA. Tuberc Res Treat. 2013;2013:129723.
Babalik A, Mannix S, Francis D, Menzies D. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J J Can Thorac Soc. 2011;18(4):225-229.
Tappero JW, Bradford WZ, Agerton TB, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis Off Publ Infect Dis Soc Am. 2005;41(4):461-469.
Park JS, Lee J-Y, Lee YJ, et al. Serum levels of antituberculosis drugs and their effect on tuberculosis treatment outcome. Antimicrob Agents Chemother. 2016;60(1):92-98.
Burhan E, Ruesen C, Ruslami R, et al. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2013;57(8):3614-3619.
Van Tongeren L, Nolan S, Cook VJ, FitzGerald JM, Johnston JC. Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2013;17(2):221-224.
Alshaikheid M, Chaabane A, Fredj NB, et al. Limited sampling strategy for predicting isoniazid exposure in patients with extrapulmonary tuberculosis. J Clin Pharm Ther. 2019;00:1-10.
Augustynowicz-Kopeć E, Zwolska Z. The type of isoniazid acetylation in tuberculosis patients treated at National Tuberculosis and Lung Diseases Research Institute. Acta Pol Pharm. 2002;59(6):443-447.
Mehiri B, Zouaoui A, Chérif J, et al. Isoniazid acetylation in a group of Tunisian patients. Report of 620 patients. Tunis Médicale. 2005;83:385-389.
Hutchings AD, Routledge PA. A single sample saliva test to determine acetylator phenotype. Br J Clin Pharmacol. 1996;42(5):635-637.
Matar K, Mayet A, Ayoola E, Bawazir S, Al-Faleh F, Al-Wazzan A. Isoniazid acetylation phenotyping in Saudi Arabs. J Clin Pharm Ther. 2004;29:443-447.
Kohno H, Kubo H, Takada A, Mori M, Arias TD. Isoniazid acetylation phenotyping in the Japanese: The molar metabolic ratio INH/AcINH. Am J Ther. 1996;3(1):74-78.
Bakayoko AS, Kamagate M, Daix ATJ, et al. Suivi thérapeutique et pharmacologique de l'isoniazide chez les patients suivis pour tuberculose pulmonaire à Abidjan. Rev Mal Respir. 2015;32:A21-A22.
Cho H-J, Koh W-J, Ryu Y-J, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberc Edinb Scotl. 2007;87:551-556.
Wang P, Pradhan K, Zhong X, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B. 2016;6(5):384-392.
World Health Organization. International Standards for Tuberculosis Care (ISTC). http://www.who.int/tb/publications/2006/istc/en/. Accessed March 7, 2020.
Moussa LA, Bouazzi OE, Serragui S, Tanani DS, Soulaymani A, Soulaymani R. Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis. Ther Adv Drug Saf. 2016;7(6):239.
Ray J, Gardiner I, Marriott D. Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Intern Med J. 2003;33(5-6):229-234.
Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow response to tuberculosis treatment in a State Control Program, Virginia, USA. Emerg Infect Dis. 2010;16(10):1546-1553.
Ali MH, Alrasheedy AA, Kibuule D, et al. Isoniazid acetylation phenotypes in the Sudanese population: findings and implications. J Clin Tuberc Mycobact Dis. 2019;17:100120.
Gupta R, Nair C, Jindal S, Malik S. Incidence of isoniazid acetylation phenotypes in North Indians. Int J Clin Pharmacol. 1984;22:259-264.
Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother. 2005;49(5):1733-1738.
Seng K-Y, Hee K-H, Soon G-H, Chew N, Khoo SH, Lee LS-U. Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers. Antimicrob Agents Chemother. 2015;59(11):6791-6799.
Hemanth Kumar AK, Kannan T, Chandrasekaran V, et al. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2016;20(9):1236-1241.
Walubo A, Chan K, Woo J, Chan HS, Wong CL. The disposition of antituberculous drugs in plasma of elderly patients. I. Isoniazid and hydrazine metabolite. Methods Find Exp Clin Pharmacol. 1991;13(8):545-550.
McIlleron H, Willemse M, Werely CJ, et al. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for International Pediatric Dosing Guidelines. Clin Infect Dis. 2009;48(11):1547-1553.
Rey E, Pons G, Gremier O, et al. Isoniazid dose adjustment in a pediatric population. Ther Drug Monit. 1998;20(1):50-55.
Aklillu E, Carrillo JA, Makonnen E, Bertilsson L, Djordjevic N. N-acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians. Eur J Clin Pharmacol. 2018;74(7):903-911.